report
indic
myeloid
plasmacytoid
dendrit
cell
mdc
pdc
key
effector
cell
host
innat
immun
respons
infect
reduc
number
function
chronic
phase
hiv
diseas
furthermor
recent
demonstr
sustain
loss
mdc
pdc
occur
sivinfect
macaqu
sinc
loss
function
dc
popul
might
impair
innat
immun
respons
opportunist
microorgan
neoplast
cell
explor
whether
inocul
naiv
sivor
shivinfect
pigtail
macaqu
hematopoiet
cytokin
would
expand
number
mdc
pdc
vivo
macaqu
receiv
supraphysiolog
dose
mdc
pdc
monocyt
increas
blood
lymph
node
bone
marrow
bm
dc
expans
bm
preced
mobil
blood
lymphoid
tissu
also
increas
serum
level
least
transient
elicit
higher
surfac
express
hladr
activ
marker
nk
cell
treatment
infect
anim
apc
increas
number
activ
howev
cell
number
virion
rna
antisivshiv
antibodi
titer
remain
rel
stabl
suggest
might
safe
modal
expand
dc
popul
provid
therapeut
benefit
chronic
lentiviru
infect
endrit
cell
dc
antigenpres
cell
apc
link
innat
adapt
immun
system
recogn
pathogen
initi
humor
cellmedi
immun
respons
two
major
type
dc
circul
human
blood
myeloid
mdc
plasmacytoid
pdc
gener
mdc
compet
pdc
present
antigen
ag
naiv
cell
howev
hoeffel
et
al
recent
show
vitro
human
pdc
crosspres
epitop
lipopeptid
uptak
ag
apoptot
cell
effici
mdc
follow
recognit
pathogenassoci
molecular
pattern
contain
bacteria
virus
tolllik
receptor
tlr
dc
subset
secret
cytokin
upregul
costimulatori
molecul
viru
activ
pdc
secret
interferon
ifn
per
cell
cell
type
call
ifnproduc
cell
furthermor
mdc
pdc
act
synergist
mediat
immun
respons
tumor
cell
enhanc
develop
activ
regulatori
treg
nk
cell
studi
mdc
pdc
typic
focu
cell
blood
dc
subset
variou
stage
develop
common
murin
macaqu
macaca
human
bone
marrow
bm
site
origin
dc
also
accumul
respiratori
mucosa
follow
allerg
stimuli
cerebrospin
fluid
bacteri
mening
induc
antivir
respons
vagin
mucosa
isol
human
tonsil
thymu
lung
liver
kidney
colon
peripher
lymph
node
ln
reduct
number
function
circul
mdc
pdc
occur
viral
infect
hepat
b
c
virus
human
cell
leukemia
viru
sar
coronaviru
other
show
dc
number
reduc
blood
secondari
lymphoid
organ
rhesu
macaca
mulatta
pigtail
macaqu
nemestrina
acut
chronic
infect
siv
character
pdc
bm
normal
pigtail
macaqu
also
reveal
cell
less
matur
phenotyp
blood
counterpart
respons
microbi
stimuli
import
initi
immun
respons
pathogen
ag
vaccin
formul
develop
novel
strategi
mobil
activ
andor
matur
dc
popul
vivo
valid
goal
myeloid
lymphoid
progenitor
cell
high
level
fmslike
tyrosin
kinas
receptor
cell
surfac
ligand
cytokin
express
tissu
highest
level
peripher
blood
mononuclear
cell
pbmc
solubl
isoform
also
present
human
blood
concentr
typic
pgml
elev
serum
patient
undergo
chemotherapi
abnorm
high
level
associ
hematolog
disord
autoimmun
diseas
initi
murin
studi
show
day
subcutan
inocul
increas
function
splenic
dc
human
stem
cell
transplant
administr
patient
elicit
increas
dc
number
enhanc
recoveri
dc
nk
cell
subset
dc
expans
subsequ
emigr
bm
first
perform
macaqu
use
regimen
effici
led
activ
increas
number
dc
blood
teleshova
et
al
show
regimen
equal
effect
similar
experi
use
chimer
granulocyt
colonystimul
factor
gcsf
receptor
agonist
progp
perform
naiv
macaqu
progp
induc
much
expans
blood
dc
increas
insuffici
augment
respons
hiv
ag
elicit
dna
vaccin
protect
macaqu
challeng
contrast
kwissa
et
al
inocul
macaqu
day
follow
immun
either
alon
cpgb
dna
ligand
plasmid
dna
recombin
vaccinia
viru
ankara
rmva
express
siv
hiv
protein
result
demonstr
day
treatment
activ
enhanc
express
mdc
monocyt
boost
twice
rmva
number
cell
express
ifng
increas
regimen
prevent
infect
immun
group
rectal
challeng
viremia
reduc
week
best
respond
receiv
cpgb
dna
although
blood
dc
activ
expand
cytokin
administr
previou
studi
clarifi
extent
mobil
occur
macaqu
tissu
especi
bm
dc
progenitor
develop
stem
cell
sinc
dc
play
import
role
innat
adapt
immun
loss
andor
impair
cell
could
exacerb
immun
dysfunct
observ
lentiviru
diseas
determin
whether
target
dc
way
enhanc
number
function
matur
viabl
therapeut
strategi
examin
kinet
activ
migrat
mdc
pdc
blood
bm
secondari
lymphoid
tissu
naiv
sivshivinfect
macaqu
adult
pigtail
macaqu
sex
use
includ
four
uninfect
macaqu
four
macaqu
infect
mean
durat
week
three
macaqu
infect
mean
durat
week
one
two
mutant
p
macaqu
macaqu
dualli
infect
week
revers
transcriptas
polymeras
chain
reaction
rtpcr
show
p
predomin
plasma
detect
sporad
pn
fultz
q
wei
piatak
j
lifson
j
hoxi
unpublish
observ
anim
inocul
subcutan
steril
human
recombin
gift
amgen
corpor
consecut
day
mg
kgday
procedur
tabl
macaqu
anesthet
intramuscular
inject
ketaminehcl
mgkg
weigh
physic
condit
heparin
blood
collect
femor
vein
pbmc
isol
densiti
gradient
centrifug
lymphocyt
separ
media
icn
biomed
inc
bm
obtain
medullari
caviti
proxim
humeru
bm
aspir
needl
medic
devic
technolog
previous
flush
heparin
yellow
fat
layer
remov
bm
edtatr
tube
ln
spleen
tissu
sampl
minc
singlecel
suspens
gener
pass
fragment
metal
cell
strainer
section
superior
lobe
lung
dissect
minc
digest
medium
supplement
mg
collagenaseml
h
pass
cell
strainer
necropsi
section
jejunum
remov
open
lengthwis
rins
phosphatebuff
salin
pb
epitheli
layer
remov
incub
medium
contain
mg
collagenaseml
min
digest
sampl
pass
cell
strainer
suspend
media
pass
two
glass
wool
column
remov
residu
epitheli
cell
contamin
red
blood
cell
lyse
hypoton
use
ammonium
chlorid
solut
mononuclear
cell
mc
resuspend
fetal
bovin
serum
fb
cryopreserv
dimethyl
sulfoxid
fb
solut
liquid
nitrogen
vapor
threeand
fourcolor
flow
cytometri
use
enumer
percentag
differ
cell
popul
character
macaqu
cell
edtatr
whole
blood
singlecel
suspens
bm
spleen
ln
tissu
cryopreserv
mc
use
experi
lymphocyt
subset
phenotyp
follow
cell
identifi
use
pacif
blueconjug
subset
distinguish
peconjug
percpconjug
nk
cell
identifi
stain
peconjug
immunotech
activ
marker
evalu
use
fitcconjug
identifi
hladr
percplabel
antihladr
lineageneg
lin
popul
use
fitcconjug
antibodi
cocktail
lin
pdc
distinguish
pelabel
mdc
substitut
pelabel
replac
fitclabel
lin
cocktail
latter
done
exclud
nk
cell
macaqu
mdc
sometim
express
low
level
coreceptor
activationmatur
molecul
evalu
use
antibodi
conjug
allophycocyanin
biotinconjug
streptavidinallophycocyanin
isotypematch
antibodi
control
fluorochrom
alway
includ
mc
gate
base
forwardandsidescatt
characterist
antibodi
reagent
purchas
bd
bioscienc
pharmingen
unless
otherwis
note
acquisit
perform
bdlsrii
siv
virion
rna
vrna
plasma
quantifi
quantit
molecular
diagnost
core
aid
vaccin
program
saic
frederick
nci
frederick
md
describ
previous
sensit
copiesml
serum
sivspecif
antibodi
titer
determin
use
crossreact
enzym
immunoassay
kit
biorad
concentr
serum
determin
use
quantikin
elisa
kit
r
system
lower
limit
detect
pgml
concentr
ifna
tumor
necrosi
factor
tnf
interleukin
il
serum
sampl
determin
use
crossreact
human
cytokin
elisa
kit
biosourc
lower
limit
detect
pgml
respect
although
upregul
hematopoiesi
cell
prolifer
mice
human
studi
macaqu
provid
limit
data
beyond
specif
myeloid
lymphoid
subset
previou
studi
examin
effect
subcutan
inocul
supraphysiolog
dose
serum
level
cytokin
normal
macaqu
day
macaqu
first
receiv
day
serum
concentr
rang
pgml
obviou
differ
infect
uninfect
anim
fig
howev
day
serum
level
increas
high
pgml
macaqu
individu
anim
increas
rang
day
concentr
highest
amount
serum
anim
rapidli
declin
last
inocul
day
two
except
infect
macaqu
maintain
high
level
pgml
day
number
circul
lymphocyt
b
nk
cell
monocyt
dc
determin
use
complet
blood
count
differenti
percentag
popul
obtain
facscan
total
number
blood
lymphocyt
inocul
appear
lower
infect
anim
compar
naiv
macaqu
mean
cell
numbersmicrolit
naiv
macaqu
lymphocyt
respect
whether
day
lymphocyt
number
naiv
outlier
includ
exclud
cohort
mean
number
lymphocyt
naiv
group
statist
greater
mannwhitney
u
test
compar
mean
anim
p
anim
combin
p
includ
p
exclud
lymphocyt
count
infect
anim
rel
stabl
treatment
wherea
total
lymphocyt
naiv
anim
fluctuat
fig
number
blood
monocyt
infect
compar
control
anim
margin
lower
day
popul
increas
group
day
fig
thrombocytopenia
common
hematolog
manifest
hivand
sivinduc
diseas
platelet
number
also
evalu
treatment
number
blood
platelet
larg
rang
macaqu
none
thrombocytopen
combin
result
anim
day
platelet
number
compar
nadir
occur
day
observ
transient
decreas
signific
p
wilcoxon
test
chang
number
pbmc
might
influenc
viru
replic
infect
anim
vrna
plasma
quantifi
anim
initi
viral
load
limit
detect
level
chang
margin
treatment
three
except
fig
increas
copiesml
day
decreas
pretreat
level
anim
viral
antibodi
titer
rang
reciproc
serum
dilut
signific
chang
titer
day
observ
treatment
consist
minim
chang
viral
load
loss
cell
hallmark
progress
lentivir
diseas
treatment
mean
number
cell
pigtail
macaqu
chronic
infect
mutant
ml
cellsml
lower
naiv
control
cellsml
chang
circul
number
mdc
pdc
associ
myeloid
lymphoid
progenitor
cell
express
receptor
therefor
exogen
administ
promot
prolifer
differenti
dc
subset
fig
inject
mean
number
blood
mdc
lower
mdcsml
respect
macaqu
compar
naiv
anim
mdcsml
fig
howev
signific
differ
mannwhitney
u
test
naiv
infect
anim
note
probabl
due
broad
distribut
mdc
small
sampl
size
group
gener
number
mdc
began
increas
day
peak
around
day
rel
increas
individu
anim
rang
differ
naiv
infect
anim
fig
rel
increas
mdc
higher
either
naiv
anim
result
slightli
greater
number
circul
mdc
number
peak
consist
previou
observ
day
mean
number
blood
pdc
lower
anim
infect
pdcsml
lesser
extent
pdcsml
compar
naiv
macaqu
pdcsml
fig
differ
statist
differ
mannwhitney
u
test
treatment
pdc
increas
much
group
total
number
remain
lower
infect
compar
naiv
anim
furthermor
peak
number
pdc
infect
cohort
greater
normal
rang
pdcsml
blood
previous
report
sivnaiv
pigtail
macaqu
although
number
pdc
naiv
macaqu
peak
day
five
seven
infect
anim
peak
occur
day
number
circul
mdc
pdc
correl
serum
level
data
shown
immun
activ
follow
administr
initi
express
activ
marker
blood
dc
administr
examin
later
cryopreserv
pbmc
obtain
either
treatment
either
day
depend
avail
use
compar
express
hladr
signific
chang
express
mfi
observ
either
mdc
pdc
anim
mdc
elev
moder
chang
mfi
approach
signific
fig
contrast
treatment
hladr
express
dc
subset
upregul
significantli
mfi
increas
much
monocyt
mdc
produc
also
secret
tnfa
cytokin
synerg
pdcsecret
ifna
induc
nk
cell
activ
promot
strong
respons
howev
hiv
infect
secret
ifna
impair
exogen
result
transient
increas
absolut
number
circul
monocyt
mdc
pdc
also
associ
higher
cell
surfac
express
hladr
therefor
determin
whether
chang
coincid
increas
concentr
dcand
monocytespecif
cytokin
day
detect
serum
anim
mean
valu
higher
naiv
compar
anim
fig
moder
increas
serum
occur
day
largest
increas
macaqu
first
inject
two
macaqu
detect
serum
ifna
tabl
macaqu
ifna
measur
earli
day
gener
day
day
serum
sampl
neg
tnfa
one
naiv
three
four
macaqu
tnfa
detect
one
occas
day
treatment
observ
concentr
tnfa
increas
greater
pgml
unusu
serum
tnfa
typic
undetect
naiv
pigtail
macaqu
infect
variou
sivshiv
strain
mdc
pdc
activ
nk
cell
either
direct
interact
indirectli
cytokin
ifna
tnfa
suggest
larger
number
circul
dc
higher
serum
cytokin
concentr
might
associ
gener
activ
prolifer
nk
cell
howev
consist
chang
observ
number
cell
increas
probabl
influenc
fluctuat
absolut
number
total
lymphocyt
occur
respons
fig
also
signific
chang
total
number
cell
nk
cell
defin
either
infect
naiv
anim
data
shown
measur
cell
activ
determin
frequenc
cell
express
receptor
use
either
marker
cell
activ
prolifer
identifi
treg
anim
increas
frequenc
cell
express
observ
mean
day
maximum
express
cell
day
respect
fig
frequenc
nk
cell
express
anoth
activ
marker
also
significantli
increas
mean
time
maximum
express
cell
day
nk
cell
day
frequenc
fig
influenc
dc
subset
macaqu
use
flow
cytometri
mdc
pdc
identifi
among
blood
mononuclear
cell
neg
lin
marker
posit
hladr
either
respect
absolut
number
mdc
b
pdc
c
initi
administr
calcul
per
millilit
blood
use
percentag
obtain
flow
cytometri
multipli
absolut
number
lymphocyt
monocyt
combin
determin
use
cbc
differenti
note
differ
scale
yax
dc
number
day
compar
peak
number
anim
group
mannwhitney
u
test
frequenc
cell
express
nk
cell
cell
cell
express
determin
throughout
studi
result
day
day
highest
percentag
activ
cell
obtain
shown
wilcoxon
sign
rank
test
nk
cell
alway
greater
cell
indic
activ
cell
phenotyp
consist
previou
observ
pigtail
macaqu
q
wei
pn
fultz
unpublish
data
increas
serum
cytokin
concentr
activ
state
nk
cell
suggest
administr
induc
peripher
immun
system
activ
coincid
matur
increas
number
circul
mdc
pdc
ascertain
effect
exogen
dc
macaqu
bm
peripher
ln
pln
multipl
singlecel
suspens
tissu
evalu
studi
rang
mdc
bm
broad
appar
differ
number
mdc
naiv
infect
anim
possibl
relat
limit
sampl
size
fig
similarli
rang
pdc
highli
variabl
indic
pdc
untreat
anim
might
lower
infect
compar
naiv
macaqu
contrast
chang
observ
blood
three
anim
day
biopsi
perform
absolut
number
mdc
pdc
bm
increas
respect
bm
biopsi
done
day
number
mdc
pdc
consist
higher
biopsi
done
eg
mdc
pdc
increas
approxim
respect
cohort
naiv
infect
anim
differ
initi
number
either
dc
subset
pln
fig
three
macaqu
pln
biopsi
perform
day
chang
either
mdc
pdc
observ
howev
mdc
pdc
anim
increas
day
stabil
decreas
largest
increas
mdc
macaqu
pdc
macaqu
mdc
pdc
enumer
mesenter
ln
mln
spleen
lung
jejunum
collect
necropsi
tabl
number
dc
tissu
vari
consider
mdc
typic
preval
pdc
consist
observ
blood
bm
pln
lung
spleen
tissu
particularli
enrich
mdc
jejunum
appear
contain
lowest
number
fig
sinc
mc
fraction
jejunum
elut
glass
wool
column
remov
epitheli
cell
mdc
exhibit
adher
properti
rk
reev
unpublish
preval
cell
jejunum
might
underestim
furthermor
although
dc
enumer
mln
spleen
lung
jejunum
anim
previous
report
pdc
frequenc
mln
spleen
sivshivinfect
uninfect
macaqu
receiv
median
number
mlnmc
uninfect
anim
respect
number
pdc
mln
macaqu
current
studi
consist
greater
tabl
regardless
viral
statu
interestingli
number
pdc
spleen
virusna
macaqu
compar
slightli
greater
number
pdc
correspond
macaqu
previous
studi
anim
greater
number
median
approxim
pdc
untreat
similarli
infect
macaqu
eg
almost
splenic
mc
result
suggest
expans
dc
tissu
blood
bm
pln
also
occur
respons
high
level
howev
caveat
tissu
data
tabl
mln
spleen
lung
jejunum
macaqu
taken
day
later
could
time
peak
dc
expans
strategi
treat
hiv
diseas
associ
hematolog
abnorm
often
test
use
macaqu
model
studi
inocul
uninfect
sivor
shivinfect
pigtail
macaqu
hematopoiet
cytokin
evalu
effect
hematolog
paramet
viremia
diseas
progress
immun
cell
activ
previou
studi
human
nonhuman
primat
inocul
quantifi
serum
concentr
evalu
anim
infect
lentiviru
normal
serum
concentr
pigtail
macaqu
similar
level
found
two
studi
healthi
human
ifnatnfa
pgml
measur
aliquot
serum
obtain
day
blood
drawn
anim
see
tabl
minu
sign
indic
undetect
anim
least
one
detect
serum
cytokin
list
serum
sampl
macaqu
neg
cytokin
tabl
pretreat
valu
compar
valu
time
shown
use
mannwhitney
u
test
ns
signific
p
p
p
horizont
bar
repres
median
valu
reev
et
al
report
median
pg
lower
mean
pg
report
cohort
cynomolgu
macaqu
fasciculari
studi
serum
increas
pgml
anim
quickli
return
baselin
level
suggest
rapid
receptormedi
uptak
andor
metabol
exogen
cytokin
find
howev
indic
peak
level
macaqu
similar
observ
human
macaqu
chemotherapeuticor
radiationinduc
aplasia
hematopoiesi
upregul
due
pancytopenia
higher
serum
concentr
coincid
higher
number
monocyt
alter
number
circul
lymphocyt
inconsist
find
agre
papayannopoul
et
al
show
cohort
naiv
pigtail
macaqu
myeloid
progenitor
mobil
greater
frequenc
lymphoid
progenitor
cell
coat
et
al
howev
report
significantli
higher
frequenc
lymphocyt
rhesu
macaqu
given
although
absolut
number
circul
lymphocyt
shown
dispar
might
reflect
minor
differ
respons
pigtail
compar
rhesu
macaqu
observ
transient
decreas
platelet
result
unexpect
sinc
report
ad
cell
cultur
inhibit
megakaryocyt
differenti
progenitor
furthermor
increas
serum
level
cynomolgu
macaqu
develop
radiationinduc
aplasia
associ
declin
platelet
treatment
counteract
effect
thrombopoietininduc
restor
platelet
count
myelosuppress
rhesu
macaqu
although
decreas
platelet
observ
minim
resolv
within
day
last
inject
possibl
therapeut
administr
advanc
lentivir
diseas
thrombocytopenia
common
might
elicit
complic
requisit
cytokin
develop
progenitor
cell
lymphoid
myeloid
lineag
bm
also
expand
mdc
pdc
deriv
progenitor
cell
peripher
lymphoid
tissu
report
expans
mdc
pdc
naiv
also
infect
macaqu
reduc
dc
number
similar
patient
compar
previou
studi
mdc
sivnaiv
rhesu
macaqu
amplifi
observ
variabl
increas
mdc
sinc
magnitud
expans
mdc
naiv
infect
macaqu
differ
gener
higher
fold
increas
studi
attribut
infect
statu
might
reflect
either
differ
rhesu
versu
pigtail
macaqu
natur
variat
among
outbr
anim
also
possibl
evalu
done
optimum
time
sinc
teleshova
et
al
found
peak
dc
expans
day
initi
regimen
day
examin
anim
magnitud
kinet
monocyt
mdc
expans
differ
significantli
naiv
infect
macaqu
peak
number
pdc
gener
occur
later
infect
day
naiv
anim
day
initi
number
pdc
blood
compar
naiv
anim
lower
suggest
immedi
pdc
precursor
might
also
lower
might
delay
increas
pdc
blood
although
viral
replic
gener
detect
anim
possibl
newli
activ
matur
pdc
suscept
lentiviru
tabl
repres
exampl
facscan
plot
shown
jejunum
lung
clearli
demonstr
larger
number
mdc
lung
jejunum
infect
might
becom
infect
destroy
thu
obscur
migrat
cell
blood
note
howev
tissu
pdc
short
halfliv
must
replenish
continu
thu
mainten
higher
number
pdc
ln
hivsiv
infect
impli
continu
migrat
cell
bm
blood
ln
would
facilit
persist
inflammatori
condit
compar
uninfect
person
activ
marker
express
dc
gener
higher
chronic
infect
found
distinct
express
compar
cell
untreat
naiv
infect
macaqu
differ
might
relat
avirem
statu
macaqu
condit
might
associ
minim
immun
system
activ
simpli
differ
virushost
interact
human
versu
macaqu
also
possibl
limit
number
anim
cohort
exhibit
full
rang
express
cell
surfac
protein
treatment
macaqu
howev
associ
increas
hladr
express
mdc
pdc
appear
upregul
anim
use
regimen
teleshova
et
al
report
signific
upregul
mdc
pdc
rhesu
macaqu
melanoma
renal
cancer
patient
hladr
upregul
dc
dc
mobil
lung
mice
express
higher
level
hladr
dc
placebotr
control
combin
data
observ
strongli
indic
gener
blood
dc
increas
number
treatment
also
activ
coincid
increas
circul
mdc
pdc
transient
higher
serum
concentr
macaqu
ifna
tnfa
consist
result
treatment
melanoma
patient
elicit
higher
serum
level
tnfa
pgml
isol
dc
macaqu
mice
produc
higher
amount
ifna
ex
vivo
similarli
vivo
administr
result
higher
amount
accumul
medium
macaqu
pbmc
cultur
ex
vivo
compar
cultur
untreat
anim
result
ifna
contrast
regard
sivinfect
macaqu
hivinfect
person
pdc
activ
produc
larg
amount
ifna
vivo
cell
refractori
stimul
vitro
consequ
produc
lower
amount
cytokin
cultur
overal
conclus
administr
macaqu
enhanc
cytokin
product
ident
specif
cell
type
tissu
compart
resid
unclear
treatment
macaqu
induc
higher
frequenc
circul
cell
like
activ
cell
possibl
might
treg
although
evalu
definit
treg
marker
would
confirm
latter
idea
mdc
pdc
known
induc
treg
develop
mechan
involv
ifna
tnfa
indoleamin
specif
acut
siv
infect
cynomolgu
macaqu
malleret
et
al
found
pdc
type
ifn
play
import
role
elicit
immunosuppress
state
furthermor
ifnab
produc
pdc
follow
hiv
infect
modul
prolifer
deplet
effector
cell
also
contribut
immunosuppress
sinc
treg
influenc
hivsiv
diseas
progress
limit
virusspecif
immun
respons
increas
popul
potenti
might
detriment
immunotherapi
hiv
howev
treg
gener
minor
proport
popul
data
also
indic
administr
upregul
activ
state
number
nk
cell
contrast
murin
studi
treatment
led
signific
increas
nk
cell
concurr
dc
mobil
increas
express
nk
cell
observ
like
link
higher
serum
activ
nk
cell
whether
activ
enhanc
lytic
activ
nk
cell
would
benefici
lentiviru
infect
nk
cell
number
function
impair
evalu
promot
cellular
activ
prolifer
therefor
major
concern
treat
lentivirusinfect
individu
cytokin
possibl
induc
viru
replic
transient
increas
viremia
detect
three
anim
similar
bucur
et
al
found
increas
viral
burden
group
rhesu
macaqu
treat
also
koopman
et
al
observ
chang
viremia
cohort
sivinfect
macaqu
treat
relat
agonist
howev
studi
vrna
plasma
increas
almost
day
suggest
potenti
might
augment
viral
replic
anim
measur
viremia
studi
use
larger
number
macaqu
higher
level
viremia
start
studi
need
address
possibl
except
thomson
group
also
evalu
ln
liver
kidney
rhesu
macaqu
previou
studi
show
mobil
dc
human
macaqu
evalu
blood
studi
util
rhesu
cynomolgu
macaqu
wherea
use
pigtail
macaquesthre
distinct
speciesthat
known
differ
physiolog
patholog
respons
siv
strain
express
ubiquit
tissu
receptor
limit
progenitor
cell
includ
dc
therefor
initi
dc
activ
occur
cell
concentr
human
verifi
site
macaqu
bm
mdc
pdc
activ
mobil
bm
appear
preced
blood
support
find
signific
correl
serum
level
dc
number
bm
mdc
r
p
pdc
r
p
blood
although
bm
damag
occur
hiv
siv
shiv
infect
obviou
dc
activ
bm
impair
infect
anim
detect
signific
increas
mdc
pdc
pln
anim
similar
previou
survey
macaqu
interest
blood
dc
number
increas
pln
day
highli
suggest
dc
origin
bm
migrat
blood
ln
detect
low
frequenc
cell
blood
ln
shown
exclud
possibl
newli
gener
dc
deriv
local
progenitor
cell
origin
directli
bm
precursor
consist
possibl
waskow
et
al
recent
show
dc
precursor
transit
bm
spleen
ln
divis
control
thu
base
preliminari
result
macaqu
chronic
infect
siv
shiv
other
show
increas
number
differ
leukocyt
subset
blood
tissu
follow
administr
macaqu
addit
studi
requir
establish
potenti
efficaci
therapi
hivinfect
person
futur
studi
comprehens
evalu
posit
neg
effect
administr
sivinfect
macaqu
nonprogressor
low
viral
load
exhibit
sign
diseas
progress
